Cystatin C Levels are Positively Correlated with both A beta(42) and Tau Levels in Cerebrospinal Fluid in Persons with Alzheimer's Disease, Mild Cognitive Impairment, and Healthy Controls
(2010) In Journal of Alzheimer's Disease 21(2). p.471-478- Abstract
- Cystatin C is suggested to be involved in neurodegeneration and the development of Alzheimer's disease (AD) by binding to soluble amyloid-beta (A beta) peptides. Studies of cystatin C levels in cerebrospinal fluid (CSF) in relation to risk of AD are conflicting and relations between cystatin C, A beta(42), and tau levels in CSF in AD, mild cognitive impairment (MCI), and healthy controls are unknown. The objective of this study was to investigate cystatin C, A beta(42), and tau levels in CSF in AD, MCI, and controls. As a secondary aim, the relationships between cystatin C, A beta(42), and tau levels across disease groups were investigated. Cystatin C, A beta(42), total tau, and phosphorylated tau levels in CSF were analyzed by... (More)
- Cystatin C is suggested to be involved in neurodegeneration and the development of Alzheimer's disease (AD) by binding to soluble amyloid-beta (A beta) peptides. Studies of cystatin C levels in cerebrospinal fluid (CSF) in relation to risk of AD are conflicting and relations between cystatin C, A beta(42), and tau levels in CSF in AD, mild cognitive impairment (MCI), and healthy controls are unknown. The objective of this study was to investigate cystatin C, A beta(42), and tau levels in CSF in AD, MCI, and controls. As a secondary aim, the relationships between cystatin C, A beta(42), and tau levels across disease groups were investigated. Cystatin C, A beta(42), total tau, and phosphorylated tau levels in CSF were analyzed by turbidimetry (cystatin C) and xMAP Luminex technology (A beta and tau) in persons with AD (n = 101), MCI (n = 84), and healthy control subjects (n = 28). Mean cystatin C levels were similar in cases of AD (5.6 mu mol/L +/- 1.7), MCI (5.4 mu mol/L +/- 1.48), and controls (5.6 mu mol/L +/- 1.6). However, CSF cystatin C levels were strongly and positively correlated with total tau and phosphorylated tau levels (r = 0.61-0.81, p < 0.0001) and A beta(42) (r = 0.35-0.65, p < 0.001) independent of age, gender, and APOE genotype. Mean CSF cystatin C levels did not differ between patients with AD and MCI and healthy controls. Interestingly, cystatin C levels were positively correlated with both tau and A beta(42) levels in CSF independent of age, gender, and APOE genotype. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/1697389
- author
- organization
- publishing date
- 2010
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- epidemiology, cystatin C, case control study, Alzheimer's disease, biomarkers, risk factor
- in
- Journal of Alzheimer's Disease
- volume
- 21
- issue
- 2
- pages
- 471 - 478
- publisher
- IOS Press
- external identifiers
-
- wos:000281887600013
- scopus:77957352489
- pmid:20555147
- ISSN
- 1387-2877
- DOI
- 10.3233/JAD-2010-091594
- language
- English
- LU publication?
- yes
- id
- b7f47be6-82a7-4447-a117-ec91e2748646 (old id 1697389)
- date added to LUP
- 2016-04-01 10:24:00
- date last changed
- 2022-03-12 05:23:28
@article{b7f47be6-82a7-4447-a117-ec91e2748646, abstract = {{Cystatin C is suggested to be involved in neurodegeneration and the development of Alzheimer's disease (AD) by binding to soluble amyloid-beta (A beta) peptides. Studies of cystatin C levels in cerebrospinal fluid (CSF) in relation to risk of AD are conflicting and relations between cystatin C, A beta(42), and tau levels in CSF in AD, mild cognitive impairment (MCI), and healthy controls are unknown. The objective of this study was to investigate cystatin C, A beta(42), and tau levels in CSF in AD, MCI, and controls. As a secondary aim, the relationships between cystatin C, A beta(42), and tau levels across disease groups were investigated. Cystatin C, A beta(42), total tau, and phosphorylated tau levels in CSF were analyzed by turbidimetry (cystatin C) and xMAP Luminex technology (A beta and tau) in persons with AD (n = 101), MCI (n = 84), and healthy control subjects (n = 28). Mean cystatin C levels were similar in cases of AD (5.6 mu mol/L +/- 1.7), MCI (5.4 mu mol/L +/- 1.48), and controls (5.6 mu mol/L +/- 1.6). However, CSF cystatin C levels were strongly and positively correlated with total tau and phosphorylated tau levels (r = 0.61-0.81, p < 0.0001) and A beta(42) (r = 0.35-0.65, p < 0.001) independent of age, gender, and APOE genotype. Mean CSF cystatin C levels did not differ between patients with AD and MCI and healthy controls. Interestingly, cystatin C levels were positively correlated with both tau and A beta(42) levels in CSF independent of age, gender, and APOE genotype.}}, author = {{Sundelof, Johan and Luoto, Johannes and Hansson, Oskar and Eriksdotter-Jonhagen, Maria and Giedraitis, Vilmantas and Larsson, Anders and Degerman-Gunnarsson, Malin and Ingelsson, Martin and Minthon, Lennart and Blennow, Kaj and Kilander, Lena and Basun, Hans and Lannfelt, Lars}}, issn = {{1387-2877}}, keywords = {{epidemiology; cystatin C; case control study; Alzheimer's disease; biomarkers; risk factor}}, language = {{eng}}, number = {{2}}, pages = {{471--478}}, publisher = {{IOS Press}}, series = {{Journal of Alzheimer's Disease}}, title = {{Cystatin C Levels are Positively Correlated with both A beta(42) and Tau Levels in Cerebrospinal Fluid in Persons with Alzheimer's Disease, Mild Cognitive Impairment, and Healthy Controls}}, url = {{http://dx.doi.org/10.3233/JAD-2010-091594}}, doi = {{10.3233/JAD-2010-091594}}, volume = {{21}}, year = {{2010}}, }